Gilead Sciences, Inc. (GILD) to Issue Quarterly Dividend of $0.82 on June 29th

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Thursday, May 7th. Investors of record on Monday, June 15th will be given a dividend of 0.82 per share by the biopharmaceutical company on Monday, June 29th. This represents a c) annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th.

Gilead Sciences has raised its dividend by an average of 0.0%annually over the last three years and has raised its dividend annually for the last 10 consecutive years. Gilead Sciences has a dividend payout ratio of 38.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Gilead Sciences to earn $9.62 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 34.1%.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $131.33 on Friday. Gilead Sciences has a 1-year low of $96.18 and a 1-year high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The firm has a fifty day simple moving average of $139.59 and a 200 day simple moving average of $132.87. The stock has a market capitalization of $163.01 billion, a PE ratio of 17.89, a P/E/G ratio of 1.77 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 49.45%. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the business earned $1.81 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts expect that Gilead Sciences will post 8.62 EPS for the current fiscal year.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Truist Financial reaffirmed its buy rating on Gilead and raised its price target to $157 from $155, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Gilead reported Q1 EPS of $2.03 and revenue of $6.96 billion, both ahead of analyst expectations, supported by HIV and Trodelvy sales growth. Yahoo Finance
• Positive Sentiment: The company raised its Yeztugo 2026 sales guidance to $1 billion from $800 million, signaling stronger-than-expected launch momentum. Yahoo Finance
• Neutral Sentiment: RBC slightly reduced its price target to $122 from $123 and kept a sector perform view, suggesting a more cautious stance but no major change in thesis. Benzinga
• Negative Sentiment: Gilead cut its 2026 EPS guidance to a loss range of -$1.05 to -$0.65, a major deterioration from prior profit expectations, due to acquisition charges and financing costs. Reuters
• Negative Sentiment: Investors also appear concerned that near-term growth is being driven more by older products like Descovy and Biktarvy than by the much-anticipated Yeztugo launch, creating questions about the pace of future growth. Yahoo Finance

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.